NEW YORK (TheStreet) -- Catalyst Pharmaceutical Partners (CPRX) - Get Report shares are up 14.2% to $3.41 on Tuesday after ROTH Capital raised the company's price target to $6 from $5 and reiterated its "buy" rating.

The upgraded outlook stems from Catalyst's positive phase III study results of Firdapse, a treatment for Lamber-Eaton Myasthenic Syndrome.

Some analysts believe that this news will lead to a prohibitive price tag of between $60,000 and $80,000 a year for the treatment.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet's Adam Feuerstein discusses the implications of the study results in depth here.

Image placeholder title

CPRX

data by

YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.